Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel for Relapsed/Refractory Multiple Myeloma.
Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, Atrash S, Smith K, Midha S, Ferreri CJ, Dhakal B, Dima D, Costello P, Wagner C, Reshef R, Hosoya H, Mikkilineni L, Atanackovic D, Chhabra S, Parrondo RD, Nadeem O, Mann H, Kalariya N, Hovanky V, DeAvila G, Freeman CL, Locke FL, Alsina M, Wong S, Herr MM, Htut M, McGuirk JP, Sborov DW, Khouri J, Martin T, Janakiram M, Lin Y, Hansen DK. Sidana S, et al. Among authors: peres lc. Blood. 2024 Oct 4:blood.2024025945. doi: 10.1182/blood.2024025945. Online ahead of print. Blood. 2024. PMID: 39365257
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Sidana S, Peres LC, Hashmi H, Hosoya H, Ferreri C, Khouri J, Dima D, Atrash S, Voorhees P, Simmons G, Sborov DW, Kalariya N, Hovanky V, Bharadwaj S, Miklos D, Wagner C, Kocoglu MH, Kaur G, Davis JA, Midha S, Janakiram M, Freeman C, Alsina M, Locke F, Gonzalez R, Lin Y, McGuirk J, Afrough A, Shune L, Patel KK, Hansen DK. Sidana S, et al. Among authors: peres lc. Haematologica. 2024 Mar 1;109(3):777-786. doi: 10.3324/haematol.2023.283940. Haematologica. 2024. PMID: 37731379 Free PMC article.
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, Freeman CL, Locke FL, Alsina M, Castaneda Puglianini O, Shune L, Sborov DW, Wagner C, Dima D, Hashmi H, Davis JA, Kocoglu MH, Badros AZ, Atrash S, Simmons G, Kalariya N, Ferreri C, Anderson LD Jr, Afrough A, Kaur G, Lin Y, Liu L, Nadeem O, Voorhees P, Khouri J, McGuirk J, Sidana S, Hansen DK, Patel K. Peres LC, et al. Blood Adv. 2024 Jan 9;8(1):251-259. doi: 10.1182/bloodadvances.2023010894. Blood Adv. 2024. PMID: 37855718 Free PMC article.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience.
Hashmi H, Hansen DK, Peres LC, Puglianini OC, Freeman C, De Avila G, Sidana S, Shune L, Sborov DW, Davis J, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Simmons G, Ferreri C, Kalariya N, Anderson LD Jr, Afrough A, Dima D, Khouri J, McGuirk J, Locke F, Baz R, Patel KK, Alsina M. Hashmi H, et al. Among authors: peres lc. Haematologica. 2024 May 1;109(5):1514-1524. doi: 10.3324/haematol.2023.283888. Haematologica. 2024. PMID: 37855036 Free PMC article.
Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience.
Khouri J, Dima D, Li H, Hansen D, Sidana S, Shune L, Anwer F, Sborov D, Wagner C, Kocoglu MH, Atrash S, Voorhees P, Peres L, Hovanky V, Simmons G, Williams L, Raza S, Afrough A, Anderson LD Jr, Ferreri C, Hashmi H, Davis J, McGuirk J, Goldsmith S, Borogovac A, Lin Y, Midha S, Nadeem O, Locke FL, Baz R, Hamilton B, Alsina M, Sauter C, Patel K, Kaur G. Khouri J, et al. Transplant Cell Ther. 2024 Aug;30(8):790.e1-790.e16. doi: 10.1016/j.jtct.2024.05.025. Epub 2024 Jun 2. Transplant Cell Ther. 2024. PMID: 38834151 Free article.
The Role of Multiple Mediation with Contextual Neighborhood Measures in Ovarian Cancer Survival.
Lawson AB, Xin Y, Peters ES, Johnson C, Hastert T, Bandera EV, Alberg AJ, Collin L, Terry P, Akonde M, Mandle H, Cote ML, Bondy M, Marks J, Peres LC, Ratnapradipa KL, Schildkraut JM. Lawson AB, et al. Among authors: peres lc. Ann Epidemiol. 2024 Oct 8:S1047-2797(24)00244-8. doi: 10.1016/j.annepidem.2024.10.002. Online ahead of print. Ann Epidemiol. 2024. PMID: 39389398
150 results